


PRODUCT: LIMKi 3**ALTERNATE NAME:** N-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methylpropanamide ; BMS 5**CATALOG #:** B1095-5, 25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₁₇H₁₄Cl₂F₂N₄OS**MOLECULAR WEIGHT:** 431.29**CAS NUMBER:** 1338247-35-0**APPEARANCE:** White Solid**SOLUBILITY:** DMSO (>40 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20°C. Protect from air and light.**DESCRIPTION:** LIMKi 3 is a potent, and cell-permeable inhibitor of LIMK1 (IC₅₀ = 7 nM) and LIMK2 (IC₅₀ = 8 nM) and inhibits coflin phosphorylation in MDA-MB-231 breast cancer cells without affecting tubulin polymerization or inducing cytotoxicity. It also reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.**REFERENCES:** Scott, R.W., *et al.* (2010). *J. Cell. Biol.* **191**, 169-185**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**LIMK1 Antibody (**3433-100**)LIMK1 Antibody (**3584-100**)**USAGE:** **FOR RESEARCH CH USE ONLY! Not to be used in humans**